112 related articles for article (PubMed ID: 21319263)
1. Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies.
Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Martin-Castillo B; Del Barco S; López-Bonet E; Menendez JA
Genes Chromosomes Cancer; 2011 Apr; 50(4):284-90. PubMed ID: 21319263
[No Abstract] [Full Text] [Related]
2. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss.
Lozy F; Cai-McRae X; Teplova I; Price S; Reddy A; Bhanot G; Ganesan S; Vazquez A; Karantza V
Autophagy; 2014 Apr; 10(4):662-76. PubMed ID: 24492513
[TBL] [Abstract][Full Text] [Related]
4. Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification.
Negri T; Tarantino E; Orsenigo M; Reid JF; Gariboldi M; Zambetti M; Pierotti MA; Pilotti S
Genes Chromosomes Cancer; 2010 Oct; 49(10):901-9. PubMed ID: 20589936
[TBL] [Abstract][Full Text] [Related]
5. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
Anastasi S; Sala G; Huiping C; Caprini E; Russo G; Iacovelli S; Lucini F; Ingvarsson S; Segatto O
Oncogene; 2005 Jun; 24(28):4540-8. PubMed ID: 15856022
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
7. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.
Bisaro B; Sciortino M; Colombo S; Camacho Leal MP; Costamagna A; Castellano I; Montemurro F; Rossi V; Valabrega G; Turco E; Defilippi P; Cabodi S
Oncotarget; 2016 Jan; 7(4):4442-53. PubMed ID: 26716506
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.
Chmielecki J; Ross JS; Wang K; Frampton GM; Palmer GA; Ali SM; Palma N; Morosini D; Miller VA; Yelensky R; Lipson D; Stephens PJ
Oncologist; 2015 Jan; 20(1):7-12. PubMed ID: 25480824
[TBL] [Abstract][Full Text] [Related]
10. Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
Arteaga CL
Clin Cancer Res; 2007 Feb; 13(4):1071-3. PubMed ID: 17317812
[No Abstract] [Full Text] [Related]
11. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
12. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
14. [Indications for treatment in invasive ductal carcinoma of the breast with Herceptin from the aspect of laboratory diagnosis--study of the ERBB-2 protein and determination of the number of copies of the ERBB2 gene. Review].
Mrhalová M; Kodet R
Cesk Patol; 2002; 38 Suppl 1():4-14. PubMed ID: 12677891
[TBL] [Abstract][Full Text] [Related]
15. Trial watch: ERBB2 dimerization inhibitor meets end point in breast cancer trial.
Nat Rev Drug Discov; 2011 Aug; 10(9):648. PubMed ID: 21878970
[No Abstract] [Full Text] [Related]
16. Successful targeting of ErbB2 receptors-is PTEN the key?
Crowder RJ; Lombardi DP; Ellis MJ
Cancer Cell; 2004 Aug; 6(2):103-4. PubMed ID: 15324690
[TBL] [Abstract][Full Text] [Related]
17. Predicting response to herceptin therapy.
Lipton A; Leitzel K; Ali S
Clin Cancer Res; 2004 Mar; 10(5):1559-60. PubMed ID: 15014003
[No Abstract] [Full Text] [Related]
18. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.
Morrison LE; Jewell SS; Usha L; Blondin BA; Rao RD; Tabesh B; Kemper M; Batus M; Coon JS
Genes Chromosomes Cancer; 2007 Apr; 46(4):397-405. PubMed ID: 17243161
[TBL] [Abstract][Full Text] [Related]
19. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Nagata Y; Lan KH; Zhou X; Tan M; Esteva FJ; Sahin AA; Klos KS; Li P; Monia BP; Nguyen NT; Hortobagyi GN; Hung MC; Yu D
Cancer Cell; 2004 Aug; 6(2):117-27. PubMed ID: 15324695
[TBL] [Abstract][Full Text] [Related]
20. Polysomy 17 and HER-2 amplification: true, true, and unrelated.
Rosenberg CL
J Clin Oncol; 2008 Oct; 26(30):4856-8. PubMed ID: 18794542
[No Abstract] [Full Text] [Related]
[Next] [New Search]